Anna Becker
Clinical Psychopharmacologist and Clinical Researcher
Key Impact
Notable for leading early-phase, placebo-controlled human trials that characterise the acute effects, safety and pharmacokinetics of classic and novel psychedelics and for investigating interactions with serotonergic antidepressants.
Background & Research
Anna Becker is a clinical psychopharmacologist whose recent work has focused on rigorous, experimental human pharmacology studies of classic and novel psychedelics. She has been a key investigator on multiple randomized, double-blind, placebo-controlled, cross-over Phase I studies in healthy volunteers that examine acute subjective and physiological effects, safety profiles and pharmacokinetics of compounds including psilocybin, LSD, mescaline, intravenous DMT and MDMA–LSD co-administration. Becker’s research frequently addresses clinically important questions such as the influence of selective serotonin reuptake inhibitors on psychedelic response and the comparative acute profiles of different serotonergic hallucinogens.
Collaboration Network
21 collaborators· click a node to visit their profile
Full network →